positive
Recently
Aktis Oncology secures Eli Lilly as anchor for upsized US IPO
Aktis Oncology is aiming for a near-$945M valuation in its US IPO, with Eli Lilly as a $100M anchor investor.
Cancer drug developer Aktis Oncology is targeting a valuation of up to $945.4 million in its upsized US initial public offering, attracting a key anchor investor in Eli Lilly, which has committed about $100 million in the deal. The company plans to offer approximately 17.7 million shares priced between $16 and $18 each, raising up to $317.7 million in the process.